NEW YORK (GenomeWeb News) – Arcxis Biotechnologies said today that it has inked a partnership with In-Q-Tel to accelerate development and commercialization of the firm's nucleic acid sample preparation platform and diagnostic consumable product line.

Arcxis said the investment from In-Q-Tel is linked to the firm's recent round of private financing led by Claremont Creek Ventures, Kaiser Permanente Ventures, and Alafi Capital. The firm has not disclosed how much money it raised in that series B round, and it is not disclosing the amount of funding it has received from In-Q-Tel.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.